Started in July 2009, our group is one of the longest-running discussion groups dedicated to patents, patent litigation and FDA regulatory issues relating to the U.S. generic drug market. Our members include top industry experts from pharma, generic drug companies, lawyers, litigators, analysts, educators, and anyone else examining generic drugs and biosimilars. No other group offers the top experts on NDA, ANDA, 505(b)(2), BLA, ABLA, 351(k), and any other drug application filed with FDA in the United States.